Zacks Investment Research cut shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a sell rating in a research note published on Wednesday morning.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

A number of other brokerages also recently commented on BCRX. HC Wainwright reiterated a buy rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, August 13th. They noted that the move was a valuation call. Bank of America upgraded BioCryst Pharmaceuticals from an underperform rating to a neutral rating in a research report on Tuesday, July 17th. BidaskClub downgraded BioCryst Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, September 15th. JPMorgan Chase & Co. initiated coverage on BioCryst Pharmaceuticals in a research report on Wednesday, August 8th. They set an overweight rating and a $9.00 price objective for the company. Finally, JMP Securities increased their price objective on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an outperform rating in a research report on Wednesday, September 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $9.89.

Shares of NASDAQ:BCRX traded down $0.39 on Wednesday, reaching $7.70. 512,158 shares of the company traded hands, compared to its average volume of 449,626. BioCryst Pharmaceuticals has a fifty-two week low of $4.25 and a fifty-two week high of $8.31. The company has a market capitalization of $875.66 million, a PE ratio of -9.87 and a beta of 1.75. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 145.89%. The company had revenue of $1.45 million for the quarter, compared to analyst estimates of $2.53 million. As a group, research analysts forecast that BioCryst Pharmaceuticals will post -0.96 EPS for the current fiscal year.

In other news, insider Thomas R. Staab II sold 14,087 shares of the stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $8.12, for a total value of $114,386.44. Following the completion of the sale, the insider now owns 138,055 shares in the company, valued at $1,121,006.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas R. Staab II sold 10,856 shares of the stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $7.84, for a total value of $85,111.04. Following the completion of the sale, the chief financial officer now owns 144,739 shares of the company’s stock, valued at approximately $1,134,753.76. The disclosure for this sale can be found here. Insiders sold 45,182 shares of company stock valued at $352,176 in the last 90 days. Corporate insiders own 4.50% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its holdings in shares of BioCryst Pharmaceuticals by 10.4% in the third quarter. Janus Henderson Group PLC now owns 12,250,161 shares of the biotechnology company’s stock valued at $93,469,000 after purchasing an additional 1,153,978 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 13.1% in the third quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock valued at $66,914,000 after purchasing an additional 1,013,905 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 10.9% in the third quarter. Jennison Associates LLC now owns 3,850,003 shares of the biotechnology company’s stock valued at $29,376,000 after purchasing an additional 378,565 shares in the last quarter. VHCP Management II LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 11.0% in the second quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock valued at $14,120,000 after purchasing an additional 243,270 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 2.2% in the second quarter. Northern Trust Corp now owns 1,214,561 shares of the biotechnology company’s stock valued at $6,960,000 after purchasing an additional 25,685 shares in the last quarter. Institutional investors own 79.82% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Further Reading: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.